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SPLUNC2    1    MLQLWKLVLLCGVLTGTSESLLDNLGNDLSNVVDKLEPVLHEGLETVDNTLKGILEK 
SPLUNC1    1 MFQTGGLIVFYGLLAQTMAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALSNGLL 
BASE       1                  MLNVSGLFVLLCG---LLVSSSAQEVLAGVSSQLLNDLTQGLL 
SPLUNC3    1           MCPLWRLLIFLGLLALPLAP--HKQPWPGLAQAHRDNKSTLARIIAQGLI 
  
SPLUNC2   58 LKVDLGVLQKSSAWQLAKQKAQEAEKLLNNVISKLLPTNT---DIFGLKISNSLILDVKA 
SPLUNC1   61 SGGLLGILENLPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELGL 
BASE      41 RADFLPSLQTTGLQKPLSSAFDGVSGLLDIFGPPLTNEIN----TVSIQVKNPQLLHVSI 
SPLUNC3   49 KHNAESRIQNIHFGDRLNASAQVAPGLVGWLISGRKHQQQ---QESSINITNIQLDCGGI 
 
SPLUNC2  115 EPIDDGKGLNLSFPVTANVTVAGPIIGQ-IINLKASLDLLTAVTIETDPQTHQPVAVLGE 
SPLUNC1  121 VQSPDGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRDKQERI-HLVLGD 
BASE      97 ESTPQRKEATVQVPFTSELIVQLLTMKP--FTANMQSDIKVQIRLEKNVGGRY-ELAFGN 
SPLUNC3  106 QISFHKEWFSANISLEFDLELRPSFDNN-IVKMCAHMSIVVEFWLEKDEFGRR-DLVIGK 
 
SPLUNC2  174 CASDPTSISLSLLDKHS-QIINKFVNSVINTLKSTVSSLLQKEICPLIRIFIHSLDVNVI 
SPLUNC1  180 CTHSPGSLQISLLDGLGPLPIQGLLDSLTGILNKVLPELVQGNVCPLVNEVLRGLDITLV 
BASE     154 CRLLP—EAIWIQTGVQLAPAQNLLWQT 
SPLUNC3  164 CDAEPSSVHVAILTEAIPPKMNQFLYNLKENLQKVLPHMVESQVCPLIGEILGQLDVKLL 
             *                                           * 
SPLUNC2  233 QQVVDNPQHKTQLQTLI 
SPLUNC1  240 HDIVNMLIHGLQFVIKV 
BASE          
SPLUNC3  224 KSLIEQEAAHEPTHHETSQPSACQAGESPS 
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Fig 1 Characterisation of SPLUNC2 antibodies by western blotting (a) The position of the two-
peptide epitopes used to generate the SPLUNC2 antibodies are illustrated (by red boxes) on a 
multiple sequence alignment of human SPLUNC proteins. The predicted amino acid sequences of 
human SPLUNC2, SPLUNC1, BASE and SPLUNC3 were aligned using CLUSTALX.  In the alignment, 
identical residues are indicated by white on black background, whereas conserved residues have the 
grey background. Spaces introduced for maximum alignments are indicated by a -. The positions of 
the conserved cysteine residues are also indicated in red (*).  (b) V5-epitope tagged SPLUNC 
proteins (SPLUNC1, SPLUNC2), were generated by coupled in vitro transcription and translation as 
outlined in the Materials and Methods section. 2µl of each reaction (and empty vector negative 
control reaction) was resolved on duplicate 12% SDS-PAGE gels alongside 5µl of whole human 
saliva. Gels were western blotted and probed with affinity purified polyclonal human SPLUNC2 
antibodies (SPLUNC2A and SPLUNC2B). The positions of the molecular markers are indicated by the 
black arrows  
83x63mm (300 x 300 DPI)  
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Fig 2 Distribution of SPLUNC2 in Major Salivary Glands Immunohistochemistry was performed on 
replicate sections as described in the Materials and Methods using the two SPLUNC2 antibodies 
(SPLUNC2A: A, D G; SPLUNC2B: B, E H) and a polyclonal antibody to SPLUNC1 (C, F, I). Tissues 
stained are Parotid gland  (A, B, C), Submandibular gland (D, E, F) and Sublingual Gland (G, H, I)  
129x84mm (300 x 300 DPI)  
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Fig 3 SPLUNC2 B immunoreactivity in parotid gland ducts Immunohistochemistry was performed on 
parotid gland with the antibody to SPLUNC2B as described in the Materials and Methods.  High 
power images were taken to show staining in the larger interlobular ducts (A) and collecting ducts 
(B). Intensely staining duct cells are indicated by the arrows. Note that the contents of the 
interlobular ducts also stain intensely  
39x58mm (300 x 300 DPI)  
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Fig 4 Distribution of SPLUNC2 in Minor Salivary Glands from the oro- and nasopharynx 
Immunohistochemistry was performed in replicate sections as described in the Materials and 
Methods using the two SPLUNC2 antibodies (SPLUNC2A: A, D, G, J; SPLUNC2B: B, E, H, K) and a 
polyclonal antibody to SPLUNC1 (C, F, I, L). Tissues stained are glands from the region of the 
palatine tonsil (A-F), glands from the posterior portion of the tongue (G-I) and glands from the 
nasal antral mucosa (J-L)  
129x105mm (300 x 300 DPI)  
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Fig 5 The human SPLUNC2 gene utilizes alternatively spliced 5’ non-coding exons 
(a) Schematic representation of the SPLUNC2 gene with the exon numbers shown below the figure. 
Coding sequence is shown in white with non-coding sequence shown in grey. The position of the 
start (exon 2) and stop codons (exon 8) are illustrated above the figure. The two 5’ non-coding 
exons are shown as 1B and 1A. The scale bar represents 1Kb. (b) Expression of alternative splicing 
of SPLUNC2 was investigated by RT-PCR with three sets of exon-spanning primer pairs as described 
in the Materials and Methods section. The primers were designed to amplify an internal portion of 
SPLUNC2 as well as the two 5’ non-coding exons  
 
83x17mm (300 x 300 DPI)  
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Fig 5 The human SPLUNC2 gene utilizes alternatively spliced 5’ non-coding exons 
(a) Schematic representation of the SPLUNC2 gene with the exon numbers shown below the figure. 
Coding sequence is shown in white with non-coding sequence shown in grey. The position of the 
start (exon 2) and stop codons (exon 8) are illustrated above the figure. The two 5’ non-coding 
exons are shown as 1B and 1A. The scale bar represents 1Kb. (b) Expression of alternative splicing 
of SPLUNC2 was investigated by RT-PCR with three sets of exon-spanning primer pairs as described 
in the Materials and Methods section. The primers were designed to amplify an internal portion of 
SPLUNC2 as well as the two 5’ non-coding exons  
 
83x36mm (300 x 300 DPI)  
 
Page 7 of 28 Histochemistry and Cell Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
  
 
 
Fig 6 SPLUNC2 is present as multiple isoforms in saliva and is N-glycosylated Western blotting was 
performed on duplicate samples of unstimulated whole saliva using antibodies SPLUNC2A (lane 1) 
and SPLUNC2B (lane 2)). In an additional experiment a further four samples of unstimulated whole 
saliva (Lanes 3-6) and a sample sublingual/submandibular gland saliva collected at the same time 
as the whole saliva sample in lane 4 (lane 7) were western blotted with antibody SPLUNC2A. A 
sample of whole saliva was subjected to deglycosylation using N-Glycanase PNGase F and subjected 
to western blotting with antibody SPLUNC2B. The multiple bands present on the mock digested 
sample (lane 8) were reduced to a single band of lower molecular mass following PNGase treatment 
(lane 9).   The positions of the molecular mass markers (30, 21 and 14kDa) are identified by the 
open arrowheads to the side of the images  
83x27mm (300 x 300 DPI)  
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 2 
 
ABSTRACT 
We recently described the PLUNC family of proteins as an extended group of proteins 
expressed in the upper airways, nose and mouth. Little is known about these proteins but 
they are secreted into airway and nasal lining fluids and saliva where, due to their 
structural similarity with lipopolysaccharide binding protein (LBP) and 
Bactericidal/permeability-increasing protein (BPI), they may play a role in innate immune 
defence. We now describe the generation and characterisation of novel affinity-purified 
antibodies to SPLUNC2, and use them to determine expression of this, the major salivary 
gland PLUNC. Western blotting showed that the antibodies identified a number of distinct 
protein bands in saliva whilst immunohistochemical analysis demonstrated protein 
expression in serous cells of the major salivary glands and in the ductal lumens as well as 
in cells of minor mucosal glands. Antibodies directed against distinct epitopes of the 
protein yielded different staining patterns in both minor and major salivary glands. Using 
RT-PCR of tissues from the oral cavity, coupled with EST analysis, we have shown that 
the gene undergoes alternative splicing using two 5’ non-coding exons, suggesting that 
the gene is regulated by alternative promoters. Comprehensive RACE analysis using 
salivary gland RNA as template, failed to identify any additional exons. Analysis of saliva 
showed that SPLUNC2 is subject to N-glycosylation. Thus our study shows that multiple 
SPLUNC2 isoforms are found in the oral cavity and suggest that these proteins may be 
differentially regulated in distinct tissues where they may function in the innate immune 
response. 
 
 
 
KEY WORDS: 
SPLUNC2, SPLUNC1, salivary glands, innate immunity, gene structure, alternative 
splicing. 
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 3 
INTRODUCTION 
We have recently described a novel family of putative host defence proteins (known as 
PLUNCs) expressed in the upper respiratory tract and oral cavity, which may serve innate 
defence functions in these locations (Bingle & Craven 2002; Bingle et al 2004; Bingle & 
Craven 2004). The founding member of this extended family, Palate Lung Nasal Clone 
(PLUNC), was first described in the nasal epithelium of the mouse embryo and the trachea 
and bronchi of adult mouse lung (Weston et al 1999). Our studies identified a family of 
human PLUNC proteins located on chromosome 20 (Bingle & Craven 2002) in close 
proximity to genes encoding the related proteins, lipopolysaccharide binding protein (LBP) 
and Bactericidal/permeability-increasing protein (BPI), key members of the innate immune 
response to Gram-negative bacteria. We have previously shown that the PLUNC family 
can be subdivided into short (SPLUNC) and long (LPLUNC) proteins containing domains 
predicted to be structurally similar to one or both domains of BPI (Bingle & Craven 2002; 
Bingle et al 2004; Bingle & Craven 2004). Due to the structural similarity to BPI and LBP 
we proposed that PLUNC proteins might function in host defence of the respiratory 
system, oro- and nasopharynx (Bingle & Craven 2002; Bingle et al 2004; Bingle & Craven 
2004; Bingle & Gorr 2004). 
Our comparative studies have revealed that PLUNC proteins are rapidly evolving and 
exhibit a high level of sequence diversity between orthologues as well as exhibiting lineage 
specific expansion in the number of paralogues (Bingle & Craven 2002; Bingle et al 2004; 
Wheeler et al 2007). The greatest diversity appears to exist in the SPLUNC portion of the 
family particularly with regard to proteins related to rodent parotid secretory protein (PSP). 
psp was identified as an abundant component of rat and mouse saliva (Madsen & Horth 
1985; Shaw & Schibler 1986; Mirels & Ball 1992) and although the identification of psp far 
predates the identification of the wider PLUNC family (Madsen & Horth 1985; Shaw & 
Schibler 1986), a biological function for psp has not been shown. A second psp-related 
protein, submandibular gland protein B (smgb) was also identified in rats (Madsen & Horth 
1985; Shaw & Schibler 1986) but is not present as a functional gene in mice (Ball et al 
2003). We have recently shown that there are 4 psp-like proteins (called bsp30a-d) in the 
bovine genome that have arisen from a series of gene duplication events (Wheeler et al 
2007).  Our comparative molecular analysis has shown that SPLUNC2 is the orthologue of 
rodent psp (Bingle & Craven 2004). It has been noted by us and others that the 
SPLUNC2/psp gene pair represents one of the most divergent human/mouse gene pairs 
and that the level of amino acid sequence identity with the rodent psp is below 35% (Emes 
et al 2003; Bingle & Craven 2004). This low level of sequence identity coupled with the 
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 4 
diversity of the SPLUNC2/psp/smgb/bsp30 proteins in general suggest that extrapolation 
of studies from one species to another may be difficult. We have previously shown that like 
its rodent counterpart, SPLUNC2 is predominantly expressed in salivary glands (Geetha et 
al 2005). The protein has also been identified in whole saliva by a number of independent 
proteomic studies (Vitorino et al 2004; Ramachandran et al 2006; Gou et al 2006; Walz et 
al 2006) as well as in minor gland saliva (Siqueira et al 2008) and as a component of 
acquired pellicle (Siqueira et al 2007). Consistent with our proposal that PLUNCs may 
function in a host defence capacity we have shown that peptides derived from SPLUNC2 
are able to inhibit LPS mediated cytokine release and also inhibit LBP/LPS interactions 
(Geetha et al 2005).  
As a prelude to the study of the biological activity of SPLUNC2 we have performed a 
systematic analysis of the human SPLUNC2 gene and studied the distribution of the 
protein in tissues of the oral cavity, nasopharynx and respiratory tract and in saliva.  
 
METHODS 
Generation and characterisation of SPLUNC2 antibodies  
Anti-peptide antibodies were generated against human SPLUNC2 by Eurogentec using 
established methods as described (Vargas et al 2008). We generated SPLUNC2 
antibodies by duel injection of two synthetic peptides corresponding to amino acids, 156-
168:  (VTIETDPQTHQPV) (designated SPLUNC2A) and amino acids 236-249-cooh:  
(VDNPQHKTQLQTLI) (designated SPLUNC2B). Pooled final serum was used for affinity 
purification against each of the individual peptides resulting in the generation of specific 
antibodies against each unique peptide. For validation of the antibodies we generated 
expression clones for human SPLUNC2 by direct cloning of PCR products into pcDNA5-
frt-V5-His-Topo (Invitrogen) which generates fusion proteins with C-terminal His and V5 
epitope tags.  Positive clones, characterised by restriction mapping and sequencing, were 
then used for coupled in vitro transcription/translation reactions (Promega) as previously 
described (Bingle et al 2005). 2µl aliquots were run on SDS-PAGE gels and western 
blotted using the specific SPLUNC2 antibodies (1:500 dilution). Detection was performed 
using ECL (Amersham) as described (Vargas et al 2008).  Fully characterised and 
sequenced clones were then used to generate stable CHO cell lines using the Flp-in Flp-
mediated recombination system according to the manufacturers instructions (Invitrogen). 
Positive lines were generated by selection in hygromycin and successful integration was 
confirmed by identifying the fusion protein in the cell pellets by western blotting using the 
V5 antibody.  Conditioned serum free media from each cell line was collected for use as 
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 5 
positive controls in western blots. The in vitro translated SPLUNC1 used for western 
blotting was generated as described (Bingle et al 2005). 
 
Saliva collection and western blotting   
Human parotid and submandibular–sublingual (SMSL) glandular salivas were stimulated 
with lemon juice and collected immediately before use from a single donor with Carlsonn 
Crittenden cups and a custom-made silicone impression device, respectively (Plummer et 
al 2006). Whole stimulated saliva was collected from several volunteers by chewing sugar-
free gum and unstimulated saliva was collected over several minutes by allowing saliva to 
pool briefly in the mouth. Whole salivas were clarified by centrifugation at 13,000g for 10 
minutes.  
Saliva samples in SDS sample buffer were resolved on 12% SDS polyacrylamide gels and 
transferred to a nitrocellulose membrane (Whatman). The membranes were blocked 
overnight at 4°C with 5% skimmed milk in Tris-buffered saline. The SPLUNC2 antibodies 
were diluted in the same blocking solution + 0.05% Tween (1:250 SP2A and 1:500 SP2B) 
and incubated with the membrane for one hour at room temperature. Membranes were 
washed in TBS/0.05% Tween before incubating for one hour with an anti-rabbit HRP 
secondary antibody. Further washing with TBS/Tween was followed by visualisation with 
ECL. 
 
Peptide: N-Glycosidase F (PNGase F) Treatment of Saliva 
PNGase F (New England Biolabs) cleaves between the innermost GlcNAc and asparagine 
residues of high mannose, hybrid, and complex oligosaccharides from N-linked 
glycoproteins. In order to determine if the multiple bands, seen on western blots of saliva 
with the SPLUNC2 antibodies, were due to glycosylation of the protein PNGase F was 
incubated with whole saliva and then western blotted. Specifically, salivas were diluted in 
denaturing buffer and heated to 100°C for 10 minutes before adding the enzyme in the 
presence of NP-40. Following a one-hour incubation at 37°C the solution was mixed with 
2X SDS sample buffer and loaded onto a 12% SDS polyacrylamide gel. The western 
blotting procedure was carried out as described above. 
 
 
Immunohistochemistry 
Ethical approval for use and processing of human tissues was granted by the Sheffield 
Research Ethics Committee. For oral, nasal, and lung tissue sections were cut from 
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 6 
formalin-fixed and paraffin-embedded tissue so as to be as representative of normal as 
possible, although all tissues were obtained from patients with an underlying clinical 
presentation. At least 3 individual samples were studied for each tissue. The slides were 
treated with 3% hydrogen peroxide in methanol to quench endogenous peroxidase, 
incubated with 100% normal goat serum at room temperature for 30 minutes and then at 
4°C overnight with the affinity purified SPLUNC2 antibodies, 1:250 (SP2A) and 1:500 
(SP2B), diluted in 100% goat serum.  We also used a polyclonal SPLUNC1 antibody 
(1:300 dilution) as described (Campos et al 2004). A rabbit IgG (DAKO) was used as a 
negative control in duplicate slides of every case. A Vectastain Elite ABC kit (Vector 
Laboratories) containing an appropriate biotin-labelled secondary antibody was used 
according to the manufacturer’s instructions. Peroxidase enzymatic development was 
performed using a Vector NovaRed substrate kit resulting in red staining in positive cells. 
Sections were counterstained with haematoxylin, dehydrated to xylene and mounted in 
DPX.  
 
Molecular characterisation and bioinfomatic analysis of the SPLUNC2 gene  
Total RNA was isolated from human salivary gland tissues, nasal epithelium and oral 
mucosa using TRI-reagent. Additional human RNA samples were purchased from 
Clontech and Ambion. All samples were provided with appropriate ethical approval. RT 
reactions were performed using oligo dT primed RNA reverse transcribed from 1µg of total 
RNA. Initial RT-PCR was performed with primers designed to amplify within the predicted 
coding region of SPLUNC2. (Forward: 5’ AAC TGA TCC CCA GAC ACA CC  3’; Reverse: 
5’ CAG AAA TGG GCC TTT ATT GC 3’). 30 cycles of the following program: 94oC for 1’, 
60oC for 2’ and 72oC for 3’ generated the appropriately sized product, which was directly 
cloned in TOPO pCRII (Invitrogen) and sequenced. SPLUNC2 ESTs were identified using 
Blast (NCBI) and the BLAT server from http://www.genome.ucsc.edu/. The genomic 
organisation confirmed by alignment of cDNAs with genomic DNA.  Transcripts containing 
both 5’ non-coding exons were identified by RT-PCR using the following forward primers. 
SP2 1AF1 5’ TGA GCA TCC TCC TCT AAA CG 3’; SP2 1AF2 5’ CAG TGG GGC AAG 
GAT TTC AT 3’; SP2 1BF1 5’ GAG GAG GCT TTG GGA ATT GT 3’ and SP2 1BF2 5’ 
GGG AAT TGT CCA GCA GAA AC 3’. A common reverse primer (as shown above) was 
used in these reactions and the resultant products were cloned into pCR 2.1TOPO and 
sequenced. Rapid amplification of cDNA ends (RACE) was performed using the SMART 
RACE system (Clontech) according to the manufacturer’s instructions. Parotid gland and 
submandibular gland total RNAs were used as templates with the following specific 
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 7 
primers; SPLUNC2RACER1 5’ GAG TGG ATG AAG ATG CGG ATC AGT GG 3’ and 
SPLUNC2RACER2 5’ GGA GGA TAC AGT GCT TTT CAG CGT GTT G 3’. RACE 
products were cloned into pCR 2.1 TOPO and colonies screened by PCR using specific 
SPLUNC2 primers. Verified SPLUNC2 clones were then fully sequenced. We also 
searched for conservation of alternative splicing of primate SPLUNC2 by cross species 
alignments of the human cDNAs with genomic DNA as well as by PCR using primate 
specific primers and rhesus monkey salivary gland cDNA (Biochain, USA) as a template. 
Again products were cloned and sequenced for verification. 
 
RESULTS 
SPLUNC2 has a distinct distribution pattern within salivary glands  
To study the localisation of human SPLUNC2 in tissues we generated two affinity purified 
anti-peptide antibodies. One of these, SPLUNC2-A, recognises an epitope that is found 
internally within the protein whilst the second antibody, SPLUNC2-B, recognises an 
epitope at the extreme C-terminus of the protein and because of the extremely low levels 
of sequence similarity between human PLUNC paralogues (Figure 1a) these antibodies 
should be highly specific. Following peptide affinity purification we characterised both 
antibodies by western blotting using in vitro translated recombinant SPLUNC2 and whole 
saliva  (Figure 1b). These results clearly show that both antibodies are able to specifically 
recognise the recombinant SPLUNC2 but no reaction was seen with SPLUNC1 produced 
in the same manner. Similar results were seen with conditioned serum-free media 
collected from stable SPLUNC2 and SPLUNC1 expressing cell lines (results not shown). 
Both antibodies were also able to identify constituents of  whole human saliva. The 
SPLUNC2A antibody recognised three clear bands, the smallest of which migrated with a 
similar apparent molecular mass to the recombinant protein generated by in vitro 
transcription/translation. The reactivity of the SPLUNC2B antibody with saliva was stronger 
than that seen with the SPLUNC2A antibody, however, it also recognised multiple bands in 
whole saliva as well as the recombinant SPLUNC2.  
 
In view of our previous observations that SPLUNC2 mRNA is expressed in salivary glands 
(Geetha et al 2005) we initially performed immunohistochemistry on sections from major 
salivary glands using both SPLUNC2 antibodies as well as an antibody to the prototypic 
SPLUNC protein, SPLUNC1. In parotid gland, both SPLUNC2 antibodies reacted with 
serous acinar cells (Figure 2A and B). SPLUNC2B appeared to stain more strongly than 
SPLUNC2A. Cells within the interlobular ducts (both striated and intercalated) also stained 
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 8 
with both antibodies. Parotid tissue did not show SPLUNC1 immunostaining (Figure 2C).  
In submandibular gland the staining pattern of the two SPLUNC2 antibodies was 
somewhat different. SPLUNC2A stained the majority of the serous acinar tissues as well 
as the interlobular ducts. The cells of the mucous tubules were clearly negative for 
SPLUNC2A (Figure 2D).  In contrast to the staining pattern described above, SPLUNC2B 
immunoreactivity was noted in only a few of the serous cells and the interlobular dusts did 
not stain (Figure 2E). Again the mucous tubule cells were clearly negative for staining. 
SPLUNC1 immunoreactivity was restricted to the mucous tubule cells (Figure 2F). A 
similar staining pattern was seen in sublingual glands (Figure 2G-H). SPLUNC2A strongly 
stained the serous demilunes whereas SPLUNC1 strongly stained the mucous secreting 
tubules. Interestingly SPLUNC2B staining was not seen in any sublingual gland samples.  
In addition to the acinar staining we also noted intense staining in some cells within the 
larger striated and collecting ducts of parotid gland samples (Figure 3A and B). In these 
regions it was striking that within individual ducts there was significant heterogeneity of 
staining (as illustrated by arrowheads in Figure 3). In these regions either single or 
doublets/triplets of cells stained very intensely, whereas their neighbouring cells were 
negative.  The lumenal content of the larger ducts also stained positively. Similar 
observations were made in sections stained with the SPLUNC2A antibody, although as 
before staining was less intense (results not shown). These findings show that SPLUNC2 
appears to be a product of the serous acini and the interlobular ducts of the major salivary 
glands cells. They further suggest that distinct protein isoforms stain in these glands. The 
results also suggest that SPLUNC2 and SPLUNC1 staining is essentially mutually 
exclusive in these glands. 
In the light of our previous observations that SPLUNC1 was a major protein product of the 
minor salivary glands of the oral cavity (Bingle et al 2005) we studied tissues from this 
region. Minor glands in the vallecular region of the tongue associated with the palatine 
tonsil also stained with both SPLUNC2 antibodies (Figure 4 A,B,D,E). In contrast to the 
situation seen in the major salivary glands where staining of SPLUNC2 and SPLUNC1 
was mutually exclusive, minor salivary glands in this region stained for both proteins 
(Figure 1A-F).  Staining was not seen in the tonsillar crypts or germinal centres. The 
staining patterns seen in the minor glands of the posterior portion of tongue was very 
similar to that seen in the sublingual gland. SPLUNC2A strongly stained the serous 
demilunes of the gland whereas SPLUNC2B staining was not seen in any samples (Figure 
4G, H). Marked SPLUNC1 staining was seen in the mucous tubules (Figure 4I).  The 
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 9 
surface epithelial layers of the tongue were not stained with either SPLUNC2 antibody 
(results not shown). 
SPLUNC2 staining was not seen in minor glands associated with the upper respiratory 
tract. Sections of maxillary sinus did not show staining in the respiratory epithelium (results 
not shown) nor did either antibody detect staining in the minor glands underlying the 
respiratory mucosa (Figure 4 J, K) where strong SPLUNC1 staining is seen.  Nasal polyps, 
tracheal and bronchial epithelium (with associated submucosal glands), were uniformly 
negative for staining with either SPLUNC2 antibody (results not shown). No staining was 
noted in peripheral lung tissues (results not shown).  
These results clearly show that SPLUNC2 protein is produced by both the major and minor 
salivary glands. In major glands staining is found in the serous acini and populations of 
epithelial cells within both interlobular and collecting ducts. This staining contrasted directly 
with the staining of the related protein SPLUNC1, which was found in mucous cells. In 
some minor glands however, SPLUNC2 and SPLUNC1 staining overlapped. The most 
striking observation that we have made is that the two SPLUNC2 antibodies exhibit distinct 
staining patterns in glands (both major and minor) that have a significant mucous cell 
component. In these, SPLUNC2B does not detect protein within the serous demilunes of 
the glands. This is best illustrated in the sublingual gland where staining was never seen, 
and in the submandibular gland where only a few serous cells stained positively (Figure 2). 
It is possible that this staining pattern is caused by one of two factors. First, distinct 
SPLUNC2 protein isoforms could potentially be generated by alternative splicing such that 
the epitopes used to produce the antibodies would not be present in all protein isoforms. 
Second, differential post-translational modification, may render the different epitopes 
unavailable for antibody binding in a tissue specific manner.  We set out to investigate 
these two possibilities  
 
SPLUNC2 is alternatively spliced and utilises distinct 5’ non-coding exons 
To investigate the first of these two possibilities we studied the genomic organisation of the 
SPLUNC2 gene in detail using sequences within public databases. This analysis allowed 
us to identify what appeared to be alternatively spliced sequences. One of these 
represented by CB985251 and AY359055 contains a novel 5’ exon approximately 7kb 
upstream of exon 2.  The second type of cDNAs, represented by BX484489, BX486580 
and BX485187 represent sequences in which either exon 5 or exon 3 read through into 
the intron. No published ESTs with internally deleted exons appear to exist in the 
SPLUNC2 gene. The organisation of the SPLUNC2 gene is shown in Figure 5A.   
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 10 
To confirm the existence of the novel upstream non-coding exon, we generated specific 
forward primers in each of the exons and used them for PCR reactions with a common 
reverse primer and with parotid and submandibular gland cDNA as templates (Figure 5B). 
These reactions generated the expected sized products with both primer pairs and both 
were confirmed by sequencing of cloned products. In addition to the major transcripts, 
reactions performed with the primers to exon 1B generated an additional band. Cloning 
this band showed that it corresponded to a further transcript with a novel 3’ end of exon 
1B.  To investigate the possibility that SPLUNC2 generates other undescribed transcripts 
we performed 5’ RACE using RNA from both parotid and submandibular gland as 
template. Using this technique we were, however, unable to amplify any additional 
transcripts containing either novel internal exons or any further upstream exons.  
Due to the extreme diversity of the SPLUNC2/psp gene sub family that we have previously 
highlighted [6] we were keen to study the evolutionary basis of the alternative 5’ exons.  
Alignment of over 1000 mouse psp ESTs with genomic DNA produced no evidence of a 
similar event in this species although some exist with a 3’ extension to the first exon 
(results not shown). However, by mapping the human SPLUNC2 cDNAs into the 
chimpanzee and rhesus monkey genomic assemblies using BLAT, we were able to predict 
that these species may contain both upstream exons.  To test this observation we 
generated forward RT-PCR primers for both of the predicted exons in rhesus monkey 
SPLUNC2 and used these with a reverse primer located in exon 9 of the rhesus monkey 
SPLUNC2 gene. Both primer sets generated the expected sized product when used with 
rhesus monkey cDNA as a template (results not shown). Cloning and sequencing of these 
products produced sequences identical to those predict d and confirmed that the rhesus 
monkey SPLUNC2 gene also utilizes two distinct 5’ non-coding exons. 
These studies clearly show that SPLUNC2 can be alternatively spliced and is presumably 
under the control of two distinct regulatory regions. However, as translation of SPLUNC2 
begins in exon 2, it is assumed that alternative splicing is not responsible for the distinct 
staining pattern seen in the immunohistochemical studies or the different bands seen in 
saliva.  For this reason we next looked at salivary proteins in greater detail. 
 
Multiple SPLUNC2 bands are detectable in human saliva 
Western blotting of a single sample of saliva showed that both SPLUNC2 antibodies 
recognize multiple bands as shown in figure 1b. To study this in greater detail we 
performed western blotting analysis using whole saliva collected from 4 individuals. When 
such samples were blotted with the SPLUNC2A antibody it was clear that there was 
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 11 
variability in the banding pattern. Most striking was the difference in the smallest band, 
which was undetectable in one sample (Figure 6 lane 4 compared to lanes 3, 5 and 6). We 
also observed that submandibular/sublingual saliva collected from the same donor as the 
whole saliva in lane 6 also exhibited a marked difference in the amount of the fastest 
migrating (i.e. smallest) band suggesting that these two major salivary glands produced 
the majority of this isoform (compare Figure 6 lanes 6 and 7). The increase of the specific 
band identified with antibody SPLUNC2-A, in the submandibular/sublingual saliva is 
consistent with a recent proteomic study, which suggested that SPLUNC2 is found at 
greater levels in saliva from this source compared with either parotid or whole saliva [16]. 
To address the issue of possible differential glycosylation of SPLUNC2 we removed N-
linked sugars on the protein in whole saliva by PNGase F treatment. This resulted in the 
reduction of the three distinct bands recognised by the SPLUNC2B antibody (Figure 6, 
lane 8) to a single band of approximately 25kDa (Figure 6, lane 9) suggesting that all three 
bands are differentially glycosylated isoforms of the same peptide. A similar removal of the 
higher mass bands from the sample blotted with SPLUNC2A was also observed (results 
not shown). This suggests that the smallest mass band in saliva represents a non-modified 
(non-glycosylated) isoform of the protein.  
 
DISCUSSION 
The PLUNC proteins make up the largest branch of the wider 
BPI/LBP/CETP/PLTP/PLUNC family of putative lipid transport proteins. The biological 
function of members of the PLUNC branch of the family is not clear, but on the basis of the 
sites at which they are expressed, there similarity to th  host defence proteins BPI and 
LBP and their status as rapidly evolving proteins, we and others have suggested that they 
may function in host defence of mucosal surfaces.  There is very little published data on 
the localisation of human PLUNC proteins with most information being available for the 
prototypic member, SPLUNC1. These have shown that the protein is predominantly 
localised to the minor mucosal glands or the oral cavity and respiratory tract as well as in a 
population of epithelial cells of the upper airways.  
We have previously shown that SPLUNC2 is expressed in a limited set of tissues with the 
most significant expression being seen in salivary glands (Geetha et al 2005). It is now 
firmly established that SPLUNC2 is the human orthologue of rodent psp despite the very 
low level of sequence similarity that exists between the two proteins (Emes et al 2003; 
Bingle et al 2004). psp was first identified as a significant component of rodent saliva and 
is known to appear during secretory granule formation in the major salivary glands in 
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 12 
postnatal development and increases to a high adult level (reviewed in Ball et al 2003). A 
second psp related protein, submandibular gland protein B (smgb) was also identified in 
rats (Mirels & Ball 1992). SPLUNC2 is not the orthologue of smgb, which appears to be a 
rodent specific member of the PLUNC gene family (Bingle et al 2004; Wheeler et al 2007). 
smgb and psp are two of the major products of the neonatal rat submandibular gland and 
both are also expressed in the sublingual and parotid glands. Expression of the two 
proteins in rats is discordant, since smgb is expressed at greater levels than psp in 
sublingual gland, whereas psp is a major parotid acinar cell product (Mirels & Ball 1992; 
Ball et al 2003). psp is produced by mouse salivary glands with similar temporal and cell 
specificity to rat psp, however, mouse smgb has been silenced through a viral integration 
event in the first intron (Ball et al 2003) and therefore mice are smgb deficient. Further 
psp-related proteins have been described in cow saliva and termed bovine salivary protein 
30 kDa (bsp30) (Wheeler et al 2002). Cloning studies initially identified two distinct genes, 
bsp30a and bsp30b, that are highly expressed in the parotid gland and comprise 
approximately 30% of the protein in bovine saliva. The two forms of bsp30 are highly 
expressed in the major salivary glands of cattle and appear to be expressed independently 
of one another (Wheeler et al 2002). bsp30a and bsp30b are highly related at primary 
sequence level (96% at DNA and 83% at amino acid level) and recent genomic analysis 
has identified the existence of two further bsp30 genes (bsp30c and bsp30d) and has 
shown that these four genes have arisen by a series of duplication events (Wheeler et al 
2007). This finding reiterates our suggestion that the SPLUNC branch of the PLUNC gene 
has undergone major diversification during mammalian evolution (Bingle et al 2004; 
Wheeler et al 2007).  
Despite multiple studies having been performed on rodent and bovine psp-related proteins 
a firm biological function for them has not been established.  There is, however, some 
evidence that supports a host defence function for these proteins. For example, psp has 
been shown to bind to bacterial membranes (Robinson et al 1997) and appears to have 
anti-candidal activity (Khovidhunkit et al 2005). The cow proteins, bsp30a and b, exhibit 
growth-suppression activity against Pseudomonas aeruginosa and Streptococcus 
pneumoniae (Haigh et al 2008).  In keeping with these studies, SPLUNC2 has also been 
shown to exhibit growth suppression effects on bacteria (Geetha et al 2003) and peptides 
derived from the protein also have anti-inflammatory effects (Geetha et al 2005) and can 
agglutinate bacteria (Gorr et al 2008). Furthermore, SPLUNC2 gene expression is 
elevated by pro-inflammatory cytokine treatment (Shiba et al 2005).  
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Consistent with the observations on expression of psp and bsp30 proteins we have shown 
that SPLUNC2 is found in both major and minor salivary glands. We have also shown that 
the protein is secreted into major gland saliva. Previously SPLUNC2 has not been 
identified in saliva by western analysis but has been identified in a number of proteomic 
studies of whole saliva, major gland saliva and, most recently, minor gland saliva (Vitorino 
et al 2004; Ramachandran et al 2006; Guo et al 2006; Walz et al 2006; Siqueira et al 
2008). Our western analysis clearly shows that multiple protein isoforms of SPLUNC2 exist 
in saliva and that these are most likely due to differential glycosylation. This observation is 
supported by a proteomic study of glycosylated proteins in whole saliva (Ramachandran et 
al 2006).  What function this differential glycosylation of SPLUNC2/psp serves, however, 
remains unclear. It is well known that many salivary proteins undergo complex post-
translational modification, including glycosylation, and it is assumed that this has a major 
effect on their function (Helmerhorst & Oppenheim 2007).  It is also note-worthy that 
rodent psp and smgb (Mirels et al 1998), as well as bovine bsp30a and b (Haigh et al 
2008) have been shown to be N-glycosylated.   
Our immunohistochemical data provides two observations of note. Firstly, the two 
SPLUNC2 antibodies exhibit discordant staining patterns in some of the salivary gland 
samples. This is particularly noticeable in both major and minor salivary glands with a 
significant mucous cell component. In some of these tissues, for example the sublingual 
gland, strong staining is seen with SPLUNC2A antibody whereas staining with SPLUNC2B 
is completely negative. We believe that this represents differences in the glycosylation 
status of the proteins within these tissues and suggest that tissue specific post-
translational modifications of SPLUNC2 may on occasion mask the epitope to which the 
antibody binds.  We do note, however, that the two N-glycosylation sites identified in a 
proteomic analysis of saliva are not within the peptide epitopes chosen for antibody 
generation (Ramachandran et al 2006).  
The second observation that we have made is that in many (but not all) glandular tissues 
SPLUNC2 and SPLUNC1 staining is mutually exclusive. Although in a few of the minor 
glands of the oral cavity the two proteins do appear to be co-localised,  for the most part 
cells positive for one protein appear to be negative for the other.  It is interesting that these 
two related proteins, which presumably share common functional activities, should be 
expressed in this manner. This observation is not unique for members of the PLUNC 
family however, as we have previously shown a similar discordant localisation of two other 
putative innate immune molecules, secretory leukocyte proteinase inhibitor (SLPI) and 
HE4 (Bingle et al 2006). These are members of the WFDC-domain containing protein 
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family that contain two structural WFDC domains (Bingle & Vayarkarnam 2008). Perhaps 
these different cellular sites of protein production ensure that there is always a significant 
source of these molecules in the saliva.  
In conclusion, we have systematically analysed the localisation of SPLUNC2 in the major 
and minor salivary glands. SPLUNC2 is predominantly expressed in the serous cells of 
major salivary glands as well as in the sero-mucus tubules of the minor glands in the oral 
mucosa, posterior tongue and tonsil.  These are all sites of production of host defence 
proteins and support our suggestion that SPLUNC2 may function in the innate immune 
defence of the oral cavity. We have also shown that the protein is present in saliva where it 
appears to exist as several differentially glycosylated protein isoforms.  It seems likely that 
these modified isoforms are also differentially distributed in the salivary glands. Analysis of 
the SPLUNC2 gene shows that it undergoes alternative splicing and utilizes two 5’ 
upstream non-coding exons that are presumably under distinct regulatory control and are 
conserved in other primates.  
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FIGURE LEGENDS 
Fig 1 Characterisation of SPLUNC2 antibodies by western blotting (a) The position of 
the two-peptide epitopes used to generate the SPLUNC2 antibodies are illustrated (by red 
boxes) on a multiple sequence alignment of human SPLUNC proteins. The predicted 
amino acid sequences of human SPLUNC2, SPLUNC1, BASE and SPLUNC3 were 
aligned using CLUSTALX.  In the alignment, identical residues are indicated by white on 
black background, whereas conserved residues have the grey background. Spaces 
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introduced for maximum alignments are indicated by a -. The positions of the conserved 
cysteine residues are also indicated in red (*).  (b) V5-epitope tagged SPLUNC proteins 
(SPLUNC1, SPLUNC2), were generated by coupled in vitro transcription and translation 
as outlined in the Materials and Methods section. 2µl of each reaction (and empty vector 
negative control reaction) was resolved on duplicate 12% SDS-PAGE gels alongside 5µl 
of whole human saliva. Gels were western blotted and probed with affinity purified 
polyclonal human SPLUNC2 antibodies (SPLUNC2A and SPLUNC2B). The positions of 
the molecular markers are indicated by the black arrows  
 
Fig 2 Distribution of SPLUNC2 in Major Salivary Glands Immunohistochemistry was 
performed on replicate sections as described in the Materials and Methods using the two 
SPLUNC2 antibodies (SPLUNC2A: A, D G; SPLUNC2B: B, E H) and a polyclonal antibody 
to SPLUNC1 (C, F, I). Tissues stained are Parotid gland  (A, B, C), Submandibular gland 
(D, E, F) and Sublingual Gland (G, H, I)  
 
Fig 3 SPLUNC2 B immunoreactivity in parotid gland ducts Immunohistochemistry was 
performed on parotid gland with the antibody to SPLUNC2B as described in the Materials 
and Methods.  High power images were taken to show staining in the larger interlobular 
ducts (A) and collecting ducts (B). Intensely staining duct cells are indicated by the arrows. 
Note that the contents of the interlobular ducts also stain intensely 
 
Fig 4 Distribution of SPLUNC2 in Minor Salivary Glands from the oro- and 
nasopharynx Immunohistochemistry was performed in replicate sections as described in 
the Materials and Methods using the two SPLUNC2 antibodies (SPLUNC2A: A, D, G, J; 
SPLUNC2B: B, E, H, K) and a polyclonal antibody to SPLUNC1 (C, F, I, L). Tissues 
stained are glands from the region of the palatine tonsil (A-F), glands from the posterior 
portion of the tongue (G-I) and glands from the nasal antral mucosa (J-L)  
 
Fig 5 The human SPLUNC2 gene utilizes alternatively spliced 5’ non-coding exons 
(a) Schematic representation of the SPLUNC2 gene with the exon numbers shown below 
the figure. Coding sequence is shown in white with non-coding sequence shown in grey. 
The position of the start (exon 2) and stop codons (exon 8) are illustrated above the figure. 
The two 5’ non-coding exons are shown as 1B and 1A. The scale bar represents 1Kb. (b) 
Expression of alternative splicing of SPLUNC2 was investigated by RT-PCR with three 
sets of exon-spanning primer pairs as described in the Materials and Methods section. The 
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primers were designed to amplify an internal portion of SPLUNC2 as well as the two 5’ 
non-coding exons  
 
Fig 6 SPLUNC2 is present as multiple isoforms in saliva and is N-glycosylated 
Western blotting was performed on duplicate samples of unstimulated whole saliva using 
antibodies SPLUNC2A (lane 1) and SPLUNC2B (lane 2)). In an additional experiment a 
further four samples of unstimulated whole saliva (Lanes 3-6) and a sample 
sublingual/submandibular gland saliva collected at the same time as the whole saliva 
sample in lane 4 (lane 7) were western blotted with antibody SPLUNC2A. A sample of 
whole saliva was subjected to deglycosylation using N-Glycanase PNGase F and 
subjected to western blotting with antibody SPLUNC2B. The multiple bands present on the 
mock digested sample (lane 8) were reduced to a single band of lower molecular mass 
following PNGase treatment (lane 9).   The positions of the molecular mass markers (30, 
21 and 14kDa) are identified by the open arrowheads to the side of the images  
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